Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IV Study of Quetiapine XR Aimed at Disability and Cognitive Impairments.

NCT00746421 is registered in ClinicalTrials.gov with Emory University as lead sponsor.

NCT NCT00746421
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00746421 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IV Study of Quetiapine XR Aimed at Disability and Cognitive Impairments.
Lead sponsor
Emory University
Phase
Phase 4
Overall status
Terminated
Start date
January 31, 2010
Completion date
April 30, 2012
Enrollment
32 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

bipolar disorder, cognitive impairment